TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05422911: Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.

Sponsor: Sun Pharmaceutical Industries Limited · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 192 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$6,837,600

Rescue Site Savings

+$4,527,600

Unlock Full NCT05422911 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05422911 Rescue Dossier →